AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
What impact does Agentic AI have on cloud-native security
How Can Organizations Safeguard Non-Human Identities in the Age of Agentic AI? How can robust management of Non-Human Identities (NHIs) and Secrets Security Management tighten
